More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab
Executive Summary
Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.
You may also be interested in...
Weak Q3 For Biocon, All Eyes On Biosimilars Approval Flow
Biocon reported a decline in profits for the third quarter but recent regulatory wins and advancements for its biosimilars portfolio could potentially bring an uptick in growth going forward.
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
The latest drug development news and highlights from our US FDA Performance Tracker.
Biocon, Dr Reddy’s Might Be Out Of The Woods On GMP Issue
Two Indian firms – Biocon and Dr Reddy’s – have received crucial establishment inspection reports (EIRs) from the US FDA amid improved compliance levels at their manufacturing sites.